{"id":"https://openalex.org/W2467078098","doi":null,"title":"Phase II clinical trial of bexarotene gel 1% in psoriasis.","display_name":"Phase II clinical trial of bexarotene gel 1% in psoriasis.","alternate_titles":[],"publication_year":2007,"publication_date":"2007-05-01","ids":{"openalex":"https://openalex.org/W2467078098","mag":"2467078098","pmid":"https://pubmed.ncbi.nlm.nih.gov/17679184"},"language":"en","primary_location":{"id":"pmid:17679184","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17679184","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of drugs in dermatology : JDD","raw_type":"Clinical Trial, Phase II"},"parent_works":[],"lineage":["https://openalex.org/W2467078098"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111604052","display_name":"Debra Breneman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I63135867","display_name":"University of Cincinnati","ror":"https://ror.org/01e3m7079","country_code":"US","type":"education","lineage":["https://openalex.org/I63135867"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Debra Breneman","raw_affiliation_strings":["University of Cincinnati College of Medicine, Department of Dermatology, Clinical Research Division, Cincinnati, OH 45219, USA. debra.breneman@uc.edu"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Cincinnati College of Medicine, Department of Dermatology, Clinical Research Division, Cincinnati, OH 45219, USA. debra.breneman@uc.edu","institution_ids":["https://openalex.org/I63135867"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113486565","display_name":"Pranav B. Sheth","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Pranav Sheth","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087030210","display_name":"Vivian Berger","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Vivian Berger","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086131899","display_name":"Vahid Naini","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Vahid Naini","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":null,"display_name":"Victor Stevens","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Victor Stevens","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.217,"has_fulltext":false,"cited_by_count":12,"citation_normalized_percentile":{"value":0.51816871,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":96},"biblio":{"volume":"6","issue":"5","first_page":"501","last_page":"506"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bexarotene","display_name":"bexarotene","score":0.8899999856948853},{"id":"https://openalex.org/keywords/topical-gel","display_name":"topical gel","score":0.8629999756813049},{"id":"https://openalex.org/keywords/plaque-psoriasis","display_name":"plaque psoriasis","score":0.9909999966621399},{"id":"https://openalex.org/keywords/retinoid-therapy","display_name":"retinoid therapy","score":0.6669999957084656},{"id":"https://openalex.org/keywords/physician-s-global-assessment","display_name":"physician global assessment","score":0.9359999895095825},{"id":"https://openalex.org/keywords/treatment-efficacy","display_name":"treatment efficacy","score":0.7250000238418579},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7689999938011169},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.41600000858306885}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9671132564544678},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8409593105316162},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.8248438835144043},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6991721987724304},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6538084745407104},{"id":"https://openalex.org/C2777501473","wikidata":"https://www.wikidata.org/wiki/Q1796666","display_name":"Body surface area","level":2,"score":0.5799731612205505},{"id":"https://openalex.org/C3020604521","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Plaque psoriasis","level":3,"score":0.5468671917915344},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5335263609886169},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.505085289478302},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5035497546195984},{"id":"https://openalex.org/C2778820923","wikidata":"https://www.wikidata.org/wiki/Q418192","display_name":"Bexarotene","level":5,"score":0.4955669641494751},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.42676085233688354},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.38911575078964233},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.07832261919975281},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C86339819","wikidata":"https://www.wikidata.org/wiki/Q407384","display_name":"Transcription factor","level":3,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C63932345","wikidata":"https://www.wikidata.org/wiki/Q422500","display_name":"Nuclear receptor","level":4,"score":0.0}],"mesh":[{"descriptor_ui":"D000077610","descriptor_name":"Bexarotene","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003879","descriptor_name":"Dermatologic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003879","descriptor_name":"Dermatologic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003879","descriptor_name":"Dermatologic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005782","descriptor_name":"Gels","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011795","descriptor_name":"Surveys and Questionnaires","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012867","descriptor_name":"Skin","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D013764","descriptor_name":"Tetrahydronaphthalenes","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013764","descriptor_name":"Tetrahydronaphthalenes","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013764","descriptor_name":"Tetrahydronaphthalenes","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":1,"locations":[{"id":"pmid:17679184","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17679184","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of drugs in dermatology : JDD","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2008712404","https://openalex.org/W1976720557","https://openalex.org/W2072250988","https://openalex.org/W4236999204","https://openalex.org/W1968732247","https://openalex.org/W2044832199","https://openalex.org/W1985223307","https://openalex.org/W1992183193","https://openalex.org/W2140539060","https://openalex.org/W2382968020"],"abstract_inverted_index":{"We":[0],"report":[1],"the":[2,11,91,103],"results":[3],"of":[4,16,41,100,105,116,125,149,161,173,204],"a":[5,84,156,170],"nonrandomized,":[6],"open-label":[7],"pilot":[8],"trial":[9],"investigating":[10],"safety,":[12],"tolerability,":[13],"and":[14,64,72,102,119,144,183,210],"efficacy":[15,81],"bexarotene":[17,49],"gel":[18,50,174,191],"1%":[19,192],"in":[20,188,195,207,220],"treating":[21,196],"chronic":[22],"mild":[23,31,185,197],"to":[24,32,66,76,94,167,198],"moderate":[25,33,187,199],"plaque":[26,35,200],"psoriasis.":[27],"Twenty-four":[28],"adults":[29],"with":[30,169,202],"stable":[34],"psoriasis":[36,101,201],"involving":[37],"15%":[38],"or":[39,140,151,186],"less":[40],"their":[42],"body":[43,106],"surface":[44,107],"were":[45,184],"enrolled.":[46],"Patients":[47],"applied":[48],"1%,":[51],"using":[52],"an":[53],"application":[54,181],"frequency":[55,172],"escalation":[56],"regimen,":[57],"starting":[58],"at":[59,131,138,180],"once":[60],"every":[61],"other":[62],"day":[63],"increasing":[65],"4":[67],"times":[68],"daily":[69],"as":[70],"tolerated":[71],"beneficial":[73],"for":[74],"up":[75],"24":[77,126],"weeks.":[78],"The":[79],"primary":[80],"instrument":[82],"was":[83,193,211],"Physician's":[85],"Global":[86],"Assessment":[87],"(PGA)":[88],"score":[89,137],"evaluating":[90],"overall":[92],"response":[93,157,165],"treatment.":[95],"This":[96],"utilized":[97],"individual":[98],"signs":[99],"percent":[104],"area":[108],"involvement.":[109],"Safety":[110],"assessments":[111],"included":[112],"physical":[113],"examinations,":[114],"recording":[115],"adverse":[117],"events,":[118],"laboratory":[120],"safety":[121],"evaluations.":[122],"Fifteen":[123],"out":[124],"enrolled":[127],"patients":[128,154,209],"(63%)":[129],"achieved":[130,147],"least":[132],"50%":[133],"improvement":[134],"by":[135],"PGA":[136],"2":[139],"more":[141],"consecutive":[142],"visits,":[143],"6":[145],"(24%)":[146],"clearing":[148],"90%":[150],"more.":[152],"Six":[153],"maintained":[155],"throughout":[158],"8":[159],"weeks":[160],"follow-up.":[162],"An":[163],"increased":[164],"appeared":[166],"correlate":[168],"higher":[171],"application.":[175],"Adverse":[176],"events":[177],"occurred":[178],"primarily":[179],"sites":[182],"severity.":[189],"Bexarotene":[190],"active":[194],"achievement":[203],"durable":[205],"responses":[206],"some":[208],"well-tolerated.":[212],"A":[213],"randomized,":[214],"placebo-controlled":[215],"study":[216],"would":[217],"be":[218],"useful":[219],"confirming":[221],"these":[222],"results.":[223]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2467078098","counts_by_year":[{"year":2023,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2013,"cited_by_count":3}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-07-22T00:00:00"}
